Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature

References

• GriffithsCEBarkerJNPathogenesis and clinical features of psoriasisLancet200737026327117658397
   PubMed Web of Science ®Google Scholar
• NaldiLEpidemiology of psoriasisCurr Drug Targets Inflamm Allergy2004312112815180464
   PubMedGoogle Scholar
• de KorteJSprangersMAMombersFMQuality of life in patients with psoriasis: a systematic literature reviewJ Investig Dermatol Symp Proc20049140147
   PubMed Web of Science ®Google Scholar
• MallbrisLAkreOGranathFIncreased risk for cardiovascular mortality in psoriasis inpatients but not in outpatientsEur J Epidemiol20041922523015117115
   PubMed Web of Science ®Google Scholar
• KremersHMMcEvoyMTDannFJHeart disease in psoriasisJ Am Acad Dermatol20075734735417433490
   PubMed Web of Science ®Google Scholar
• GelfandJMTroxelABLewisJDThe risk of mortality in patients with psoriasis: results from a population-based studyArch Dermatol20071431493149918086997
   PubMed Web of Science ®Google Scholar
• GelfandJMNeimannALShinDBRisk of myocardial infarction in patients with psoriasisJAMA20062961735174117032986
   PubMed Web of Science ®Google Scholar
• SchmittJMFordDERole of depression in quality of life for patients with psoriasisDermatology2007215172717587835
   PubMed Web of Science ®Google Scholar
• GuptaMASchorkNJGuptaAKSuicidal ideation in psoriasisInt J Dermatol1993321881908444530
   PubMed Web of Science ®Google Scholar
• SternRSNijstenTFeldmanSRPsoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfactionJ Investig Dermatol Symp Proc20049136139
   PubMed Web of Science ®Google Scholar
• JavitzHSWardMMFarberEThe direct cost of care for psoriasis and psoriatic arthritis in the United StatesJ Am Acad Dermatol20024685086012063481
   PubMed Web of Science ®Google Scholar
• SchmittJFordDEWork Limitations and Productivity Loss are Associated with Health-related Quality of Life but not with Clinical Severity in Patients with PsoriasisDermatology2006213110
   Web of Science ®Google Scholar
• MenterAGriffithsCECurrent and future management of psoriasisLancet200737027228417658398
   PubMed Web of Science ®Google Scholar
• NastAKoppIBAugustinM[S3-Guidelines for the therapy of psoriasis vulgaris]J Dtsch Dermatol Ges20064 Suppl 2S112617187649
   PubMedGoogle Scholar
• British Association of DermatologistsPsoriasis Guideline 2006 Available at http://www.library.nhs.uk/guidelinesfinder/ViewResource.aspx?resID=1253232006British Association of Dermatologists 31=1-2008
   Google Scholar
• MosmannTRCherwinskiHBondMWTwo types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986J Immunol200517551415972624
   PubMed Web of Science ®Google Scholar
• NickoloffBJCracking the cytokine code in psoriasisNat Med20071324224417342112
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet20083711675168418486740
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet20083711665167418486739
   PubMed Web of Science ®Google Scholar
• KimballABGordonKBLangleyRGSafety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trialArch Dermatol200814420020718283176
   PubMed Web of Science ®Google Scholar
• EMEAEuropean Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab)19 Feb2009Londonm, UKEMEA
   Google Scholar
• SchotteliusAJMoldawerLLDinarelloCABiology of tumor necrosis factor-alpha-implications for psoriasisExp Dermatol20041319322215086336
   PubMed Web of Science ®Google Scholar
• WakefieldPEJamesWDSamlaskaCPTumor necrosis factorJ Am Acad Dermatol1991246756851869638
   PubMed Web of Science ®Google Scholar
• DavenportCMMcAdamsHAKouJInhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitisInt Immunopharmacol2002265367212013505
   PubMed Web of Science ®Google Scholar
• NickoloffBJKarabinGDBarkerJNCellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasisAm J Pathol19911381291401702929
   PubMed Web of Science ®Google Scholar
• KristensenMChuCQEedyDJLocalization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75-kD TNF receptorClin Exp Immunol1993943543628222328
   PubMed Web of Science ®Google Scholar
• EttehadiPGreavesMWWallachDElevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesionsClin Exp Immunol1994961461518149659
   PubMed Web of Science ®Google Scholar
• BonifatiCCarducciMCordialiFPCorrelated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients–relationships with disease severityClin Exp Dermatol1994193833877955493
   PubMed Web of Science ®Google Scholar
• MussiABonifatiCCarducciMSerum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasisJ Biol Regul Homeost Agents1997111151189498161
   PubMed Web of Science ®Google Scholar
• UyemuraKYamamuraMFivensonDFThe cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated responseJ Invest Dermatol19931017017057693825
   PubMed Web of Science ®Google Scholar
• PartschGWagnerELeebBFUpregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluidJ Rheumatol1998251051109458212
   PubMed Web of Science ®Google Scholar
• RitchlinCHaas-SmithSAHicksDPatterns of cytokine production in psoriatic synoviumJ Rheumatol199825154415529712099
   PubMed Web of Science ®Google Scholar
• HohlerTKrugerASchneiderPMA TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritisJ Invest Dermatol19971095625659326391
   PubMed Web of Science ®Google Scholar
• BeyaertRDe PotterCVanhaesebroeckBInduction of inflammatory cell infiltration and necrosis in normal mouse skin by the combined treatment of tumor necrosis factor and lithium chlorideAm J Pathol19911387277391848044
   PubMed Web of Science ®Google Scholar
• PalladinoMABahjatFRTheodorakisEAAnti-TNF-alpha therapies: the next generationNat Rev Drug Discov2003273674612951580
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskogLSassoEHTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther200811724427918155297
   PubMed Web of Science ®Google Scholar
• SabatRPhilippSHoflichCImmunopathogenesis of psoriasisExp Dermatol20071677979817845210
   PubMed Web of Science ®Google Scholar
• BoehnckeWHPrinzJGottliebABBiologic therapies for psoriasis. A systematic reviewJ Rheumatol2006331447145116724367
   PubMed Web of Science ®Google Scholar
• KempeniJPreliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7Ann Rheum Dis199958 Suppl 1I70I7210577977
   PubMedGoogle Scholar
• EMEASCIENTIFIC DISCUSSION, Humira (Adalimumab) Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/humira/400803en6.pdfaccessed March 24, 20092004
   Google Scholar
• FDAPackage insert Humira (adalimumab) U.S. Govt. Lic. No. 0043Abbott Laboratories Available at http://www.fda.gov/Cder/foi/label/2002/adalabb123102LB.htmaccessed March 24, 20092002
   Google Scholar
• WeismanMHMorelandLWFurstDEEfficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyClin Ther2003251700172112860493
   PubMed Web of Science ®Google Scholar
• DeRuiterJRileyTNHow can adalimumab (Humira) be used to treat rheumatoid arthritis?US Pharmacist [serial online]2003285
   Google Scholar
• SantoraLCKaymakcalanZSakorafasPCharacterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcoreAnal Biochem200129911912911730333
   PubMed Web of Science ®Google Scholar
• TjioeMGerritsenMJDen BroederAAAdalimumab, a fully human anti-TNF-alpha monoclonal antibody, treatment does not influence experimental UV response in the skin of rheumatoid arthritis patientsExp Dermatol20031246046512930303
   PubMed Web of Science ®Google Scholar
• FredrikssonTPetterssonUSevere psoriasis--oral therapy with a new retinoidDermatologica1978157238244357213
   PubMedGoogle Scholar
• FelsonDTAndersonJJBoersMAmerican College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisArthritis Rheum1995387277357779114
   PubMed Web of Science ®Google Scholar
• GordonKBLangleyRGLeonardiCClinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyJ Am Acad Dermatol20065559860617010738
   PubMed Web of Science ®Google Scholar
• MenterATyringSKGordonKAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJ Am Acad Dermatol20085810611517936411
   PubMed Web of Science ®Google Scholar
• SauratJHStinglGDubertretLEfficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)Br J Dermatol200815855856618047523
   PubMed Web of Science ®Google Scholar
• RevickiDAMenterAFeldmanSAdalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III studyHealth Qual Life Outcomes200867518831744
   PubMed Web of Science ®Google Scholar
• RevickiDWillianMKSauratJHImpact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisBr J Dermatol200815854955718047521
   PubMed Web of Science ®Google Scholar
• RevickiDAWillianMKMenterAImpact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisJ Dermatolog Treat20071834135018058494
   PubMed Web of Science ®Google Scholar
• ShikiarRHeffernanMLangleyRGAdalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trialJ Dermatolog Treat200718253117365264
   PubMed Web of Science ®Google Scholar
• NijstenTSpulsPIAdalimumab may be better or no worse than methotrexate in the treatment of psoriasisBr J Dermatol200815925725818489593
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJRitchlinCTAdalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis Rheum20075647648817265483
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDRitchlinCTAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialArthritis Rheum2005523279328916200601
   PubMed Web of Science ®Google Scholar
• MeasePJOryPSharpJTAdalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)Ann Rheum Dis20096970270918684743
   PubMed Web of Science ®Google Scholar
• GenoveseMCMeasePJThomsonGTSafety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapyJ Rheumatol2007341040105017444593
   PubMed Web of Science ®Google Scholar
• RevickiDAWillianMKMenterARelationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasisDermatology200821626027018187944
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJCifaldiMAAdalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis TrialAnn Rheum Dis20076616316817046964
   PubMed Web of Science ®Google Scholar
• PapoutsakiMChimentiMSCostanzoAAdalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologicsJ Am Acad Dermatol20075726927517574299
   PubMed Web of Science ®Google Scholar
• HeibergMSKoldingsnesWMikkelsenKThe comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter studyArthritis Rheum20085923424018240258
   PubMed Web of Science ®Google Scholar
• VanLModiSVYangDJSustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatmentArch Dermatol200814480480618559778
   PubMed Web of Science ®Google Scholar
• SeitzMWirthmullerUMollerBThe -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patientsRheumatology (Oxford)200746939616720636
   PubMed Web of Science ®Google Scholar
• TutuncuZKavanaughAZvaiflerNFcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agentsArthritis Rheum2005522693269616142749
   PubMed Web of Science ®Google Scholar
• NelsonAAPearceDJFleischerABJrCost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment periodJ Am Acad Dermatol20085812513517996329
   PubMed Web of Science ®Google Scholar
• SiztoSBansbackNFeldmanSREconomic evaluation of systemic therapies for moderate to severe psoriasisBr J Dermatol2008Dec 13 [Epub ahead of print]
   Web of Science ®Google Scholar
• GoldbergLDThe convergence of psoriasis treatment cost-effectiveness over time: “real world” considerations in economic modelingJ Am Acad Dermatol2008581073107518485990
   PubMed Web of Science ®Google Scholar
• RouxCHBrocqOBreuilVPregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapyRheumatology (Oxford)20074669569817158212
   PubMed Web of Science ®Google Scholar
• BerthelotCNGeorgeSJHsuSDistal lower extremity paresthesia and foot drop developing during adalimumab therapyJ Am Acad Dermatol200553S260S26216227104
   PubMed Web of Science ®Google Scholar
• ChungJHVan StavernGPFrohmanLPAdalimumab-associated optic neuritisJ Neurol Sci200624413313616527311
   PubMed Web of Science ®Google Scholar
• FulchieroGJJrSalvaggioHDrabickJJEruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapiesJ Am Acad Dermatol200756S65S6717434043
   PubMed Web of Science ®Google Scholar
• GeorgeSJAndersonHLHsuSAdalimumab-induced urticariaDermatol Online J200612416638397
   PubMedGoogle Scholar
• SmithDIHeffernanMPVitiligo after the resolution of psoriatic plaques during treatment with adalimumabJ Am Acad Dermatol200858S50S5218191709
   PubMed Web of Science ®Google Scholar
• WuJJTsaiTFRecurrent hyperglycemia during adalimumab treatment in a patient with psoriasisArch Dermatol20081441403140418936418
   PubMed Web of Science ®Google Scholar
• ShethNGreenblattDPatelSAdalimumab-induced cutaneous lupusClin Exp Dermatol20073259359417692063
   PubMed Web of Science ®Google Scholar
• DengAHarveyVSinaBInterstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitorsArch Dermatol200614219820216490847
   PubMed Web of Science ®Google Scholar
• TubachFRavaudPSalmon-CeronDEmergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonistsClin Infect Dis200643e95e10017051484
   PubMed Web of Science ®Google Scholar
• DalmauJRoeECorellaFAcute generalized skin eruption due to adalimumab: report of two casesJ Eur Acad Dermatol Venereol2007211105110617714134
   PubMed Web of Science ®Google Scholar
• WollinaUHanselGKochATumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patientsAm J Clin Dermatol2008911418092839
   PubMed Web of Science ®Google Scholar
• PapadavidEGaziSDalamagaMPalmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for managementJ Eur Acad Dermatol Venereol20082238038218269613
   PubMed Web of Science ®Google Scholar
• ZangrilliAPapoutsakiMTalamontiMLong-term efficacy of adalimumab in generalized pustular psoriasisJ Dermatolog Treat20081918518718569276
   PubMed Web of Science ®Google Scholar
• CallenJPJacksonJHAdalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescentJ Dermatolog Treat20051635035216428160
   PubMed Web of Science ®Google Scholar
• StincoGPiccirilloFPatronePHypertriglyceridaemia during treatment with adalimumab in psoriatic arthritisBr J Dermatol20071571273127417916219
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care1992304734831593914
   PubMed Web of Science ®Google Scholar
• McHorneyCAWareJEJrRaczekAEThe MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructsMed Care1993312472638450681
   PubMed Web of Science ®Google Scholar
• FinlayAYKhanGKDermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical useClin Exp Dermatol1994192102168033378
   PubMed Web of Science ®Google Scholar
• BrazierJJonesNKindPTesting the validity of the Euroqol and comparing it with the SF-36 health survey questionnaireQual Life Res199321691808401453
   PubMed Web of Science ®Google Scholar
• PatelTGordonKBAdalimumab: efficacy and safety in psoriasis and rheumatoid arthritisDermatol Ther20041742743115379777
   PubMedGoogle Scholar
• MossnerRSchonMPReichKTumor necrosis factor antagonists in the therapy of psoriasisClin Dermatol20082648650218755367
   PubMed Web of Science ®Google Scholar
• RicheldiLAn update on the diagnosis of tuberculosis infectionAm J Respir Crit Care Med200617473674216799073
   PubMed Web of Science ®Google Scholar
• LalvaniADiagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemyChest20071311898190617565023
   PubMed Web of Science ®Google Scholar
• DohertySDVan VoorheesALebwohlMGNational Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agentsJ Am Acad Dermatol20085920921718485527
   PubMed Web of Science ®Google Scholar
• Bouwes BavinckJNHardieDRGreenAThe risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up studyTransplantation1996617157218607173
   PubMed Web of Science ®Google Scholar
• JensenPHansenSMollerBSkin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimensJ Am Acad Dermatol19994017718610025742
   PubMed Web of Science ®Google Scholar
• EuvrardSKanitakisJClaudyASkin cancers after organ transplantationN Engl J Med20033481681169112711744
   PubMed Web of Science ®Google Scholar
• SaladiRNPersaudANThe causes of skin cancer: a comprehensive reviewDrugs Today (Barc)200541375315753968
   PubMed Web of Science ®Google Scholar
• MarcilISternRSSquamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover studyLancet20013581042104511589933
   PubMed Web of Science ®Google Scholar
• MohanNEdwardsETCuppsTRDemyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritidesArthritis Rheum2001442862286911762947
   PubMed Web of Science ®Google Scholar
• TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupNeurology19995345746510449104
   PubMed Web of Science ®Google Scholar
• CollamerANGuerreroKTHenningJSPsoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of actionArthritis Rheum200859996100118576309
   PubMed Web of Science ®Google Scholar
• LeeHHSongIHFriedrichMCutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonistsBr J Dermatol200715648649117300238
   PubMed Web of Science ®Google Scholar
• ScheinfeldNAdalimumab: a review of side effectsExpert Opin Drug Saf2005463764116011443
   PubMedGoogle Scholar
• KirshenCKanigsbergNAlopecia areata following adalimumabJ Cutan Med Surg200913485019298772
   PubMed Web of Science ®Google Scholar
• GarciaBNLeeHHWormMDevelopment of alopecia areata universalis in a patient receiving adalimumabArch Dermatol20061421654165517179003
   PubMedGoogle Scholar
• SimisterNEPlacental transport of immunoglobulin GVaccine2003213365336912850341
   PubMed Web of Science ®Google Scholar
• CepedaEJWilliamsFMIshimoriMLThe use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic diseaseAnn Rheum Dis20086771071218079191
   PubMed Web of Science ®Google Scholar
• AslanidisSVassiliadisTPyrpasopoulouAInhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two casesClin Rheumatol20072626126416924392
   PubMed Web of Science ®Google Scholar
• SchmittJZhangZWozelGEfficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trialsBr J Dermatol200815951352618627372
   PubMed Web of Science ®Google Scholar
• RichSJConsiderations for assessing the cost of biologic agents in the treatment of psoriasisJ Manag Care Pharm200410S38S4115253689
   PubMedGoogle Scholar
• SteinKRPearceDJFeldmanSRThe impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis careSemin Cutan Med Surg200524525715900799
   PubMed Web of Science ®Google Scholar
• BurmesterGRMeasePJDijkmansBAAdalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesAnn Rheum Dis2009Jan 15 [Epub ahead of print]
   Web of Science ®Google Scholar